Substantial Revenues and Earnings Plus for Ge... ( DUSSELDORF Germany July 14 2010 ...)

Substantial Revenues and Earnings Plus for Gerresheimer

Date:7/14/2010

    DUSSELDORF, Germany, July 14, 2010 /PRNewswire-FirstCall/ --

    - Group Revenues in the Second Quarter up by 6.8% (Excluding
      Technical Plastic Systems)

    - Further Solid Growth of the Pharma Business - Improvement in
      the Cosmetics and Life Science Research Segments

    - Operating (Adjusted EBITDA) Margin at High Level of 20.9%

    - Profit From Operations More Than Doubled to EUR 24.8m

    - Revenue Guidance for 2010 Specified and Margin Guidance
      Raised

Gerresheimer AG, one of the leading worldwide suppliers to the pharma and healthcare industry, remained on its growth path during the second quarter of the financial year 2010. "Our business developed very well in the second quarter. The demand for our products in the pharma industry has grown and there has also been an improvement recently in the Cosmetics and Life Science Research businesses," says Uwe Rohrhoff, the new CEO of Gerresheimer AG since June 22, 2010.

In the period from March to May 2010, the company increased its revenues (excluding the Technical Plastic Systems business which has been sold) by 6.8% compared with the prior year. At constant exchange rates the growth rate in the second quarter was 5.6%. During the first six months of the financial year 2010, the revenue growth at constant exchange rates was 3.6%. Revenues in the second quarter totaled EUR 268.8m (second quarter of 2009 excl. Technical Plastic Systems: EUR 251.6m). In addition to sales growth in the segment of primary pharmaceutical packaging, Gerresheimer profited from the improvement in the more cyclical Cosmetics and Life Science Research businesses in the second quarter.

The operating margin (Adjusted EBI
'/>"/>

SOURCE Gerresheimer AG
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5
Related medicine technology :

1. Medivations MDV3100 Demonstrates Substantial PSA Reductions in First Patient Groups Treated in Phase 1-2 Hormone Refractory Prostate Cancer Trial
2. TREANDA Demonstrates Substantial Efficacy in Patients with Relapsed Indolent Non-Hodgkins Lymphoma
3. REMICADE-Treated Patients Experienced Rapid and Substantial Improvement in Psoriasis in Critical Regions of Body
4. NKTR-118 Shows Substantial Oral Bioavailability and Extended Half-Life in Phase 1 Clinical Data Presented at American Pain Society Meeting
5. New International Study Shows Women With Symptomatic Fibroids Delaying Treatment Despite Substantial Burden on Quality of Life
6. Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2009 Goals at JPMorgan Healthcare Conference
7. Study Shows Otamixaban Substantially Reduced Complications of Invasive Management of Acute Coronary Syndromes
8. Sanofi Aventis: Study Shows Otamixaban Substantially Reduced Complications of Invasive Management of Acute Coronary Syndromes
9. Pharma Billionaire Stewart Rahr Provides Substantial Donation to Haiti Charities
10. New Research Shows Over-use of Asthma Rescue Inhalers Substantially Reduced Through Pharmacist-initiated Physician Intervention
11. Delcath Systems Reports Substantial Progress

Post Your Comments:

(Date:5/24/2013)... -- In accordance with Rule 17.1 and Rule 2.9 of ... States Exchange Act, Echo Pharma Acquisition Limited ("Royalty Pharma") today ... ELN). Background On 2 May 2013, ... the entire of the issued and to be issued share ... On 20 May 2013, Royalty Pharma announced the ...

(Date:5/23/2013)... Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA ) ... Life Science Firm of the Year by the Tech Council ... at the TCM,s 25 th Annual Tech Awards Celebration ... Awards Celebration recognizes the leaders and innovators in the technology ... and the surrounding regions. "We are deeply ...

(Date:5/23/2013)... , May 23, 2013 Nephros, Inc. (OTC ... medical device company that develops and sells high performance ... its rights offering. In addition, the concurrent temporary reduction ... expired on May 17, 2013. Nephros estimates ... from the rights offering. A portion of the proceeds ...

Breaking Medicine Technology:Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 2 Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 3 Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 4 Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 5 Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 6 Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 7 Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 8 Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 9 Vanda Pharmaceuticals Named the 2013 Life Science Firm of the Year by the Tech Council of Maryland 2 Nephros Announces Completion of Rights Offering 2 Nephros Announces Completion of Rights Offering 3 Nephros Announces Completion of Rights Offering 4

[0] Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements [0] Vanda Pharmaceuticals Named the 2013 Life Science Firm of the Year by the Tech Council of Maryland [0] Nephros Announces Completion of Rights Offering

... 2010 New research from Lloydspharmacy reveals that whilst an ... sympathy levels at that time of the month appear to ... or fairly compassionate, a quarter of women (25%) who have ... unsympathetic. The survey shows that period pain ...

... Biotechnology Corporation ( www.generex.com ) (OTC Bulletin Board: ... date of its previously announced acquisition of a controlling interest ... 1, 2011. The Company also announced its receipt ... Listing and Hearing Review Council affirming the decision of the ...

Cached Medicine Technology:Lloydspharmacy Reveals Couples Beleaguered by Monthly Cramps 2 Generex Announces Extension of Global Medical Direct Acquisition Closing Date 2 Generex Announces Extension of Global Medical Direct Acquisition Closing Date 3

Lloydspharmacy Reveals Couples Beleaguered by Monthly Cramps Generex Announces Extension of Global Medical Direct Acquisition Closing Date

(Date:5/25/2013)... MA (PRWEB) May 25, 2013 Imagine running ... -- the energy loss, hot air and wasted energy! If ... house fan, a fireplace or clothes dryer, that may be ... Drafts from these often overlooked holes waste energy in the ... of heating and cooling loss in the home. , Drafts ...

(Date:5/25/2013)... 25, 2013 Dr. Leslie Gerstman ... FDA-approved to lift skin on the neck, on the brow ... practice, Medical Aesthetics. , Ultherapy is a non-surgical procedure for ... healing process to lift the skin over time. The use ... to see and then treat the deepest support layers of ...

(Date:5/25/2013)... 25, 2013 Communities of Distinction TV ... is the fifth largest media market in the United States ... one visitor destination in Texas and a major convention city. ... American West as it is home to many major museums. ... from sports to the arts. Residents and locals will be ...

(Date:5/25/2013)... and parasites that affect both dogs and humans, such ... can result in liver or kidney failure -- may ... These germs could be found in the ... Nelson, a clinical associate professor at Kansas State University,s ... be fatal, even with treatment," she said in a ...

(Date:5/25/2013)... May 25, 2013 Radius Engineering ... shelter company in the US and has been ... for over 35 years. M.E. and President, Walton ... of NBC Weapon Fundamentals and Shelter Engineering Standards, ... bible on shelter engineering. McCarthy is considered the ...

Breaking Medicine News(10 mins):Health News:How To Stop Drafts and Save On Home Energy Bills This Summer - New Draft Stoppers Now Available From Battic Door Energy Conservation 2 Health News:How To Stop Drafts and Save On Home Energy Bills This Summer - New Draft Stoppers Now Available From Battic Door Energy Conservation 3 Health News:How To Stop Drafts and Save On Home Energy Bills This Summer - New Draft Stoppers Now Available From Battic Door Energy Conservation 4 Health News:Dr. Leslie Gerstman Is Now Offering the Non-surgical Facelifting Procedure – Ultherapy – in NYC and NJ 2 Health News:Communities of Distinction TV Presents May Air Dates for Dallas-Ft. Worth, Texas 2 Health News:Hidden Dangers Dog Dog Parks 2 Health News:Radius Engineering International Inc. Offers Tools to Stay Safe and Recover From Any Disaster 2 Health News:Radius Engineering International Inc. Offers Tools to Stay Safe and Recover From Any Disaster 3

[0] How To Stop Drafts and Save On Home Energy Bills This Summer - New Draft Stoppers Now Available From Battic Door Energy Conservation [0] Dr. Leslie Gerstman Is Now Offering the Non-surgical Facelifting Procedure – Ultherapy – in NYC and NJ [0] Communities of Distinction TV Presents May Air Dates for Dallas-Ft. Worth, Texas [0] Hidden Dangers Dog Dog Parks [0] Radius Engineering International Inc. Offers Tools to Stay Safe and Recover From Any Disaster

... , PALM CITY, Fla., Aug. ... pleased to announce its decision to offer discount dental plans ... collaboration with DentalPlans.com, the leading online provider of discount dental ... offer Connectyx,s MedFlash(TM) product to its members. This collaboration is ...

... SHENZHEN, China, Aug. 27 /PRNewswire-Asia/ -- On August 10, 2009, ... the,"Company") entered into a contract with a machine producer in ... , This new machineries will constitute ... and operated in the Company,s,subsidiary in Huanggang, and it is ...

... Aug. 27 Mylan Inc. (Nasdaq: MYL ) ... to market 1% Clindamycin and 5% Benzoyl Peroxide Gel based ... subsidiary of Valeant Pharmaceuticals International. The preparation is the first ... the U.S. Food and Drug Administration (FDA). , ...

... , , DUBLIN, Ohio, Aug. 27 ... up to an aggregate purchase price of $1.2 billion of its ... is part of a previously announced plan to reduce the company,s ... Corp. and includes notes issued by both Cardinal Health and one ...

... , , NASHVILLE, ... (Nasdaq: CPIX ), a specialty pharmaceutical company focused on ... 2009 financial results. , , "Our second quarter ... events in the Company,s history--receipt of Food and Drug Administration (FDA) ...

... ST. PAUL, Minn., Aug. 27 The need for blood ... blood. From premature infants to an organ transplant recipient who will typically ... is urgent. , , We are currently ... can be given to save the life of anyone, from premature infants ...

Connectyx Technologies Offers MedFlash Members Access to 30+ Discount Dental Plans from DentalPlans.com Winner Medical Purchased New Purcotton Production Line to Meet Increasing Demand Mylan Begins Marketing First Generic Version of BenzaClin(R) Acne Treatment Cardinal Health Announces $1.2 Billion Debt Tender Offer Cumberland Pharmaceuticals Reports Second Quarter 2009 Financial Results Memorial Blood Centers in Urgent Need of Type O Negative and Type B Negative Blood Donors

... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...

... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...

... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...

... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...

Medicine Products:

Ketaject K1, Vitamin, Serum Itraconazole, Antifungal Serum Level, HPLC Isopropyl Alcohol